Genelux Co. (NASDAQ:GNLX) Major Shareholder Aladar Szalay Sells 31,376 Shares

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 31,376 shares of the stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $2.62, for a total transaction of $82,205.12. Following the transaction, the insider now directly owns 664,678 shares in the company, valued at $1,741,456.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Monday, September 9th, Aladar Szalay sold 23,383 shares of Genelux stock. The shares were sold at an average price of $2.70, for a total value of $63,134.10.
• On Tuesday, September 3rd, Aladar Szalay sold 42,818 shares of Genelux stock. The stock was sold at an average price of $2.09, for a total value of $89,489.62.
• On Thursday, August 29th, Aladar Szalay sold 107,045 shares of Genelux stock. The shares were sold at an average price of $1.98, for a total transaction of $211,949.10.
• On Tuesday, August 27th, Aladar Szalay sold 51,630 shares of Genelux stock. The shares were sold at an average price of $2.11, for a total transaction of $108,939.30.
• On Friday, August 23rd, Aladar Szalay sold 40,000 shares of Genelux stock. The stock was sold at an average price of $2.29, for a total transaction of $91,600.00.

Genelux Stock Performance

Shares of NASDAQ:GNLX traded up $0.09 during midday trading on Wednesday, reaching $2.60. 113,445 shares of the company’s stock were exchanged, compared to its average volume of 188,853. The company’s 50 day simple moving average is $2.19 and its two-hundred day simple moving average is $3.48. Genelux Co. has a 12 month low of $1.60 and a 12 month high of $30.44. The firm has a market capitalization of $89.32 million, a PE ratio of -2.68 and a beta of -1.55.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). On average, research analysts anticipate that Genelux Co. will post -0.9 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Woodward Diversified Capital LLC grew its stake in Genelux by 0.3% during the first quarter. Woodward Diversified Capital LLC now owns 1,085,957 shares of the company’s stock worth $6,983,000 after buying an additional 3,687 shares during the last quarter. Vanguard Group Inc. increased its holdings in Genelux by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 1,023,030 shares of the company’s stock valued at $6,578,000 after purchasing an additional 24,220 shares in the last quarter. Armistice Capital LLC bought a new position in Genelux in the 2nd quarter valued at $1,755,000. Highbridge Capital Management LLC acquired a new position in Genelux in the second quarter worth $1,231,000. Finally, Affinity Asset Advisors LLC bought a new stake in shares of Genelux during the second quarter worth $195,000. 37.33% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $32.00 price objective on shares of Genelux in a research note on Thursday, August 15th. Roth Mkm initiated coverage on Genelux in a research report on Tuesday, August 27th. They issued a “buy” rating and a $10.00 price target on the stock. Roth Capital raised shares of Genelux to a “strong-buy” rating in a research report on Tuesday, August 27th. Finally, Benchmark cut their price target on Genelux from $30.00 to $25.00 and set a “speculative buy” rating for the company in a report on Friday, May 31st. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $26.75.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.